Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become established as blood glucose-lowering therapies that should be considered in people with type 2 diabetes if glycemic targets are not met with lifestyle measures and metformin [1], especially in those with, or at high risk of, cardiovascular disease (CVD) [2]. Here, GLP1R is linked to cardiovascular disorder.